Henry Ford Optimeyes Optometrist Medicare: Medicare Enrolled Practice Location: 7230 Orchard Lake Rd, W Bloomfield, MI 48322 Phone: 248-661-5100 |
News Archive
Pharmasset, Inc. announced today the pricing of an underwritten public offering of 3,300,000 shares of its common stock at an offering price of $46.33 per share. Of the shares being sold, Pharmasset is selling 2,300,000 shares and the selling stockholders are selling 1,000,000 shares. Pharmasset expects to receive net proceeds, after deducting the underwriting discount and estimated offering expenses, of approximately $101.5 million.
Genentech, a member of the Roche Group, today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint of a significant improvement in the time people with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse (progression-free survival, PFS).
Curemark, LLC,, a drug research and development company focused on the treatment of neurological diseases, announced that the company has opened clinical trial enrollment for CM-AT, its autism treatment, at the University of Pittsburgh and the Alexian Brothers Behavioral Health Hospital in Hoffman Estates, Illinois, near Chicago. A total of 12 sites nationwide are recruiting patients for CM-AT Phase III clinical trials.
The study, done by Harvard researchers and published by the New England Journal of Medicine, was based on Gallup polling and data from the Department of Health and Human Services.
The brand name of a drug can strongly influence treatment decisions by patients, according to a randomized trial of decision aids by researchers from McMaster University.
› Verified 5 days ago